| 摘要 |
Despite recent progress in the investigation and therapy of colorectal cancer (CRC),
the disease still remains one of the major causes of cancer-related deaths worldwide.
In the past decade, with the introduction of new cytotoxic and targeting agents,
significant improvements have been made in response rates, progression-free
survival, and overall survival of metastatic colorectal cancer (mCRC) patients. In
spite of these improvements, a significant number of CRC patients undergo
chemotherapy for advanced disease without any significant benefit, and may suffer
from severe adverse effects. In this post-genomic era, the individualization of cancer
chemotherapy through the study of pharmacogenetics is becoming an everattainable
goal. Pharmacogenetic studies and pharmacogenomics (a polygenic
approach to pharmacogenetic studies) have shown that polymorphisms in genes
related to drug metabolism, transport, and drug targets contribute to interindividual
differences in drug efficacy and toxicities. Validation of predictive and prognostic
molecular markers will enable clinicians in the tailoring of chemotherapy for each
patient based on the molecular profile of both the patient and tumor. Currently I am
focusing on the results of studies assessing the effects of gene polymorphisms in drug
metabolizing enzymes and drug targets on the response and toxicity to commonly
used clinical anticancer drugs for CRC patients, with the purpose of selecting the
optimal drug therapy and dosage for each patient. |
